On monster molecules
For all our enthusiasm for novel early stage niches in oncology, let’s not forget the overall probability of success in preclinical and phase 1 development are both low.
When assessing these opportunities it is important to keep our feet on the ground and general perspectives on a sensible level.
Despite the risks, however, I can see this particular category seeing more activity from large pharmas once they have completed their annual strategic review periods going into AACR.
The good news is there is always another Gleevec, Avastin, Keytruda, Enhertu etc lurking in the wings somewhere. The challenge is predicting where they might come from.
In this review we explore an emerging landscape and point out the potential upsides, downsides, and biotech players coming through because this isn’t a big Pharma space, at least for now…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers